Daily Intelligence Brief
Daily Docket: PowerPort Jury Awards $40M as Fekkai Suit Hits S.D.N.Y.
These event summaries are AI-generated and still in beta. Pending our full analytics build-out, please verify critical dates independently. Spot something off? Let us know.
A District of Arizona jury on Friday returned a $40 million plaintiff verdict for Kimberly Divelbliss in the second bellwether of the Bard Implanted Port Catheter Products Liability Litigation (3081), the proceeding U.S. Senior District Judge David G. Campbell is overseeing. The JPML counted 3,734 actions pending as of Sept. 1. The trial concerned a fractured PowerPort catheter. Additional bellwethers are set for Oct. 13, Dec. 1, and Feb. 2, 2027. The first bellwether, tried in May, produced a defense result on failure-to-warn and a hung jury on design defect.
We tracked 120 new filings across 16 litigations. The Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047) added 51 — 43% of the day and 12% of its 417 trailing-30-day filings — with Frantz Law Group APLC filing 30 and Weitz & Luxenberg PC 10. Keller Postman LLC filed all 24 in the Zantac (Ranitidine) Products Liability Litigation (2924). Krentsel & Guzman LLP filed all 11 in the Aqueous Film-Forming Foams Personal Injury Products Liability Litigation (2873). The Glucagon-Like Peptide-1 Receptor Agonists Products Liability Litigation (3094) added 3, one each through Flint Cooper, Laborde Earles, and Morgan & Morgan PA. U.S. District Judge Karen Spencer Marston reset the MDL's evidentiary hearing to Sept. 14–18 in Courtroom 16B.
Sex-abuse and trafficking matters supplied 16 filings. Frederic Fekkai removed Merson Law's Frederic Fekkai Epstein Sex Abuse Litigation from New York Supreme Court to the S.D.N.Y., a seven-plaintiff Gender-Motivated Violence Protection Act action alleging Fekkai and salon employee Patrick Coombs enabled Epstein's abuse. The Uber Passenger Sexual Assault Litigation (3084) added 9, five through Chaffin Luhana LLP. The G6 Hospitality Sex Trafficking Litigation added 6, five through The Byrd Law Firm and Douglas & London.
Practitioner Note: The PowerPort docket now has a plaintiff damages verdict on a fracture theory after a mixed first trial. Social Media remains the day's volume engine. That Frantz concentration is inventory, not a new legal event.
Australian Senate Opens Paraquat Inquiry
Australia’s Senate launched a Senate inquiry on Sept. 8 into the continued use and regulation of paraquat, putting the herbicide’s safety record and its alleged Parkinson’s disease connection before a federal committee. The Rural and Regional Affairs and Transport References Committee will examine the evidence considered by the Australian Pesticides and Veterinary Medicines Authority, its decision-making process and the consequences for agricultural workers and rural communities. The committee set an Oct. 22 submissions deadline, creating a near-term forum for competing scientific and regulatory positions after the authority retained paraquat under new restrictions in June. The inquiry does not determine causation or liability, but it creates a current government record that can sharpen the evidence fight in paraquat product-liability cases.
Japan’s PFAS Source-Attribution Dispute Deepens
At a Sept. 8 government press briefing, Japan’s Ministry of Defense declined to confirm whether U.S. Forces Japan had identified Kadena Air Base and Marine Corps Air Station Futenma as likely PFAS sources during a 2023 consultation. The ministry maintained that it cannot definitively establish a causal relationship between contamination found near Okinawan bases and U.S. military facilities, even as the disclosure renewed pressure for access to investigate the sites. That official refusal leaves the source-identification dispute live rather than resolving it through a government admission. For Aqueous Film-Forming Foams Personal Injury Products Liability (2873), the dispute underscores how military-base PFAS claims can turn on proof tying contamination to firefighting-foam use and allocating responsibility among potential sources.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
